| Literature DB >> 28870262 |
Sourour Neji1,2, Ines Hadrich3, Houaida Trabelsi1,2, Salma Abbes2, Fatma Cheikhrouhou1,2, Hayet Sellami1,2, Fattouma Makni1,2, Ali Ayadi1,2.
Abstract
BACKGROUND: The aim of this study was to determine the biofilm formation, the extracellular enzymatic activities of 182 clinical isolates of the Candida parapsilosis complex.Entities:
Keywords: Antifungal susceptibility; Biofilm production; Candida parapsilosis Complex; Haemolysin; Mechanisms of resistance; Phospholipases; Proteases; Virulence factors
Mesh:
Substances:
Year: 2017 PMID: 28870262 PMCID: PMC5582387 DOI: 10.1186/s12929-017-0376-2
Source DB: PubMed Journal: J Biomed Sci ISSN: 1021-7770 Impact factor: 8.410
The sequences of primers and probes used in RT-qPCR
| Gene | Primers and probes | |
|---|---|---|
| ACT1 | F | 5′- CGAACGTGGTTACGGTTTCT- 3’ |
| R | 5′- TGACCATCTGGCAATTCGTA - 3’ | |
| Probe | TET-TGCAAACCTCATCACAATCA-MGB | |
| CDR1 | F | 5′- GCTGTTGATCAAAGGGGTGT - 3’ |
| R | 5′- ATCCAAAATCCAGGCAACTG - 3’ | |
| Probe | FAM- CTGATAATGCCGCCAATCTT-MGB | |
| ERG11 | F | 5′- TGTTGCATTTGGCTGAGAAG - 3’ |
| R | 5′- TCTGAGGGTTTCCTTGATGG - 3’ | |
| Probe | FAM-GGTAAAGGTGGCAACTTGGA-MGB | |
| MDR1 | F | 5′- TCCCCATTGCTATTGTTGGT - 3’ |
| R | 5′- TGCGCCCATATAATTGAACA - 3’ | |
| Probe | FAM- TTGGTCGGCAACGACATATA-MGB | |
| MRR1 | F | 5′- CAGCTGCAACAACCACAACT - 3’ |
| R | 5′- TATCATCTAGGCCGCCATTC - 3’ | |
| Probe | FAM- GCAACCACAGCCTATAGGGA-MGB |
Level of phospholipase, caseinase, gelatinase and hemolysin production by C. parapsilosis complex species and C. albicans
| Phospholipase activity | Caseinase activity | Gelatinase activity | Hemolysin activity | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean ( | Strong | Moderate | Weak | Nul | Mean ( | Strong | Moderate | Weak | Nul | Mean ( | Strong | Moderate | Weak | nul | Mean ( | Strong | Moderate | Weak | nul | |
|
| 0.86 | 16 | 92 | 3 | 71 | 0.51 | 156 | 10 | 1 | 15 | 0.71 | 85 | 91 | 0 | 6 | 0.62 | 141 | 41 | 0 | 0 |
|
| 0.85 | 16 | 92 | 3 | 61 | 0.5 | 150 | 6 | 1 | 15 | 0.71 | 81 | 85 | 0 | 6 | 0.61 | 137 | 35 | 0 | 0 |
|
| 1 | 0 | 0 | 0 | 6 | 0.72 | 2 | 4 | 0 | 0 | 0.72 | 3 | 3 | 0 | 0 | 0.81 | 1 | 5 | 0 | 0 |
|
| 1 | 0 | 0 | 0 | 4 | 0.49 | 4 | 0 | 0 | 0 | 0.71 | 1 | 3 | 0 | 0 | 0.63 | 3 | 1 | 0 | 0 |
|
| 0.62 | 26 | 2 | 0 | 4 | 0.69 | 19 | 9 | 4 | 0 | 0.72 | 7 | 25 | 0 | 0 | 0.7 | 15 | 16 | 1 | 0 |
N: number of tested isolates
n: number of isolates with positive activity for the corresponding hydrolytic enzyme
SD: standard deviation
Distribution of enzymatic activities from C. parapsilosis complex species isolated from different clinical sites
| Phospholipase activity | Caseinase activity | Gelatinase activity | Hemolysin activity | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Blood ( | 0.82 ± 0.12 | 1 | 1 | 0.46 ± 0.13 | 0.71 | 0.49 | 0.7 ± 0.07 | 0.65 | 0.65 | 0.6 ± 0.09 | 0.87 | 0.73 |
| Urine ( | 0.89 ± 0.12 | 1 | 1 | 0.52 ± 0.21 | 0.67 | 0.46 | 0.71 ± 0.11 | 0.8 | 0.73 | 0.62 ± 0.1 | 0.86 | 0.65 |
| Auricular sample ( | 0.88 ± 0.12 | 1 ± 0 | 1 | 0.59 ± 0.22 | 0.73 ± 0.15 | 0.59 | 0.71 ± 0.08 | 0.74 ± 0.14 | 0.75 | 0.62 ± 0.08 | 0.75 ± 0.09 | 0.51 |
| Respiratory tract ( | 0.88 ± 0.15 | 0 | 0 | 0.45 ± 0.05 | 0 | 0 | 0.67 ± 0.04 | 0 | 0 | 0.62 ± 0.08 | 0 | 0 |
| Catheter ( | 0.88 ± 0.12 | 0 | 0 | 0.39 ± 0.03 | 0 | 0 | 0.68 ± 0.02 | 0 | 0 | 0.61 ± 0.1 | 0 | 0 |
| Skin ( | 0.82 ± 0.14 | 1 | 0 | 0.38 ± 0.04 | 0.72 | 0 | 0.71 ± 0.14 | 0.67 | 0 | 0.6 ± 0.11 | 0.84 | 0 |
| Nails ( | 1 ± 0 | 0 | 0 | 0.44 ± 0.02 | 0 | 0 | 0.78 ± 0.01 | 0 | 0 | 0.5 ± 0.01 | 0 | 0 |
| Oral cavity ( | 0.84 ± 0.07 | 0 | 0 | 0.49 ± 0.13 | 0 | 0 | 0.7 ± 0.03 | 0 | 0 | 0.57 ± 0.07 | 0 | 0 |
| Vagina ( | 0.89 | 0 | 0 | 0.35 | 0 | 0 | 0.67 | 0 | 0 | 0.64 | 0 | 0 |
| Peritoneal fluid ( | 0.74 | 0 | 0 | 0.47 | 0 | 0 | 0.8 | 0 | 0 | 0.57 | 0 | 0 |
| Hand carriage ( | 0.82 ± 0.13 | 0 | 1 | 0.56 ± 0.2 | 0 | 0.44 | 0.76 ± 0.09 | 0 | 0.71 | 0.65 ± 0.11 | 0 | 0.63 |
N: number of tested isolates
n: number of isolates with positive activity for the corresponding hydrolytic enzyme
SD: standard deviation
Biofilm production from C. parapsilosis complex species isolated from different clinical sites
|
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|
| N | Mean Abs ± SD | Range | N | Mean Abs ± SD | Range | N | Mean Abs | Range | |
| Blood ( | 62 | 0.415 ± 0.625 | 0.009–3.093 | 1 | 0.055 | 0.055–0.055 | 1 | 0.304 | 0.304–0.304 |
| Urine ( | 29 | 0.770 ± 0.949 | 0.016–3.903 | 1 | 0.094 | 0.094–0.094 | 1 | 0.564 | 0.564–0.564 |
| Auricular sample ( | 39 | 0.347 ± 0.347 | 0.003–1.559 | 3 | 0.080 ± 0.056 | 0.031–0.142 | 1 | 0.191 | 0.191–0.191 |
| Respiratory tract ( | 4 | 0.804 ± 0.615 | 0.172–1.612 | 0 | 0 | 0 | 0 | 0 | 0 |
| Catheter ( | 9 | 0.611 ± 0.562 | 0.080–1.776 | 0 | 0 | 0 | 0 | 0 | 0 |
| Skin ( | 7 | 0.334 ± 0.372 | 0.044–1.070 | 1 | 0.061 | 0.061–0.061 | 0 | 0 | 0 |
| Nails ( | 2 | 0.953 ± 1.303 | 0.032–1.875 | 0 | 0 | 0 | 0 | 0 | 0 |
| Oral cavity ( | 3 | 1113 ± 0,718 | 0.283–1.547 | 0 | 0 | 0 | 0 | 0 | 0 |
| Vagina ( | 1 | 0.824 | 0.824–0.824 | 0 | 0 | 0 | 0 | 0 | 0 |
| Peritoneal fluid ( | 1 | 0.263 | 0.263–0.263 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hand carriage ( | 15 | 0.182 ± 0.174 | 0.021–0.482 | 0 | 0 | 0 | 1 | 0.145 | 0.145–0.145 |
| Total ( | 172 | 0.475 ± 0.633 | 0.003–3.903 | 6 | 0.075 ± 0.038 | 0.031–0.142 | 4 | 0.301 ± 0.187 | 0.145–0.564 |
N: number of tested isolates
n: number of isolates with positive activity for the corresponding hydrolytic enzyme
SD: standard deviation
In vitro susceptibility of C. parapsilosis complex species to eight antifungal drugs
|
|
|
| |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Range | Mean | S % | SDD % | R % | Range | Mean | S % | SDD % | R % | Range | Mean | S % | SDD % | R % | |
| Fluconazole | 0.25–32 | 2.427 | 83.64 | 10.91 | 5.45 | 0.5–1 | 0.833 | 100 | 0 | 0 | 0.25–0.5 | 0.437 | 100 | 0 | 0 |
| Itraconazole | 0.008–0.5 | 0.096 | 83.64 | 16.36 | 0 | 0.016–0.125 | 0.078 | 100 | 0 | 0 | 0.016–0.064 | 0.052 | 100 | 0 | 0 |
| Ketoconazole | 0.008–16 | 0.321 | ND | ND | ND | 0.008–0.016 | 0.013 | ND | ND | ND | 0.008–0.016 | 0.010 | ND | ND | ND |
| Posaconazole | 0.008–1 | 0.106 | ND | ND | ND | 0.016–0.08 | 0.040 | ND | ND | ND | 0.032–0.08 | 0.052 | ND | ND | ND |
| Voriconazole | 0.008–8 | 0.190 | 90.91 | 7.27 | 1.82 | 0.008–0.032 | 0.018 | 100 | 0 | 0 | 0.008–0.016 | 0.010 | 100 | 0 | 0 |
| Caspofungin | 0.032–1.5 | 0.426 | 100 | 0 | 0 | 0.064–0.25 | 0.136 | 100 | 0 | 0 | 0.064–0.25 | 0.126 | 100 | 0 | 0 |
| Amphotericin B | 0.016–1 | 0.293 | 100 | 0 | 0 | 0.064–0.5 | 0.240 | 100 | 0 | 0 | 0.064–0.25 | 0.172 | 100 | 0 | 0 |
| 5-Flucytosine | 0.03–2 | 0.110 | 100 | 0 | 0 | 0.03–0.03 | 0.030 | 100 | 0 | 0 | 0.03–0.064 | 0.055 | 100 | 0 | 0 |
ND Not determined due to lack of validated clinical breakpoints, S susceptible, SDD dose-dependent susceptible, R resistant
Fig. 1Study of the level of expression of ERG11, CDR1, MDR1 and MRR1 genes by relative quantification with RT-qPCR in Candida parapsilosis: 12 susceptible strains (green bars), 6 dose-dependent susceptible strains (yellow bars) and 4 resistant strains (red bars). Error bars represent the relative maximum (RQ max) and minimum (RQ min) quantifications with one standard deviation
Antifungal susceptibility to the azoles and relative quantification of gene expression and gene copy number of ERG11, CDR1, MDR1 and MRR1 genes in Candida parapsilosis
| Strain | Posaconazole | Fluconazole | Itraconazole | Ketoconazole | Voriconazole | RNA relative quantification | DNA relative quantification | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC | I | MIC | I | MIC | I | MIC | I | MIC | I | ERG11 | CDR1 | MDR1 | MRR1 | ERG11 | CDR1 | MDR1 | MRR1 | |
| TN157HC02 | 0,016 | ND | 0,5 | S | 0,064 | S | 0,008 | ND | 0,008 | S | 1153 | 0,527 | 1259 | 1169 | 1367 | 2042 | 1087 | 3437 |
| TN180HC04 | 0,032 | ND | 0,25 | S | 0,125 | S | 0,008 | ND | 0,008 | S | 0,445 | 2296 | 0,379 | 0,696 | 0,317 | 12,977 | 0,203 | 0,227 |
| TN330HC04 | 0,032 | ND | 0,5 | S | 0,016 | S | 0,008 | ND | 0,008 | S | 0,595 | 0,693 | 0,901 | 0,733 | 6578 | 9570 | 6364 | 7141 |
| TN176HC05 | 0,064 | ND | 1 | S | 0,064 | S | 0,016 | ND | 0,016 | S | 0,489 | 0,309 | 0,781 | 0,589 | 0,296 | 0,217 | 0,019 | 0,034 |
| TN419HC05 | 0,016 | ND | 0,5 | S | 0,008 | S | 0,008 | ND | 0,008 | S | 0,314 | 1045 | 0,053 | 0,117 | 0,357 | 0,461 | 0,105 | 0,958 |
| TN597HC06 | 0,032 | ND | 1 | S | 0,064 | S | 0,016 | ND | 0,016 | S | 0,367 | 1890 | 0,074 | 0,081 | 0,773 | 1613 | 0,247 | 3938 |
| TN81HC07 | 0,032 | ND | 0,25 | S | 0,032 | S | 0,008 | ND | 0,008 | S | 0,579 | 1457 | 0,524 | 2108 | 1961 | 1597 | 3665 | 0,895 |
| TN123HC07 | 0,032 | ND | 0,5 | S | 0,032 | S | 0,016 | ND | 0,032 | S | 1123 | 1729 | 0,327 | 0,731 | 0,973 | 0,766 | 1061 | 1971 |
| TN826HC08 | 0,016 | ND | 1 | S | 0,064 | S | 0,008 | ND | 0,016 | S | 1525 | 0,538 | 0,584 | 0,909 | 1421 | 1220 | 1257 | 0,979 |
| TN28HC09 | 0,08 | ND | 1 | S | 0,064 | S | 0,008 | ND | 0,016 | S | 1046 | 1196 | 2352 | 1166 | 0,929 | 1005 | 0,866 | 0,562 |
| TN144HC09 | 0,125 | ND | 2 | S | 0,032 | S | 0,016 | ND | 0,016 | S | 0,948 | 0,378 | 0,312 | 0,364 | 0,502 | 1006 | 0,343 | 2949 |
| TN14HC11 | 0,032 | ND | 0,25 | S | 0,064 | S | 0,008 | ND | 0,008 | S | 1644 | 0,077 | 0,000 | 0,052 | 0,261 | 1877 | 0,495 | 1913 |
| TN70HC02 | 0,5 | ND | 4 | SDD | 0,5 | SDD | 0,064 | ND | 0,125 | S | 2115 | 1841 | 2192 | 2812 | 4434 | 7221 | 3060 | 13,487 |
| TN377HC03 | 0,5 | ND | 4 | SDD | 0,25 | SDD | 0,125 | ND | 0,125 | S | 3518 | 12,990 | 13,401 | 25,498 | 0,506 | 2129 | 0,327 | 2977 |
| TN19HC08 | 0,5 | ND | 4 | SDD | 0,25 | SDD | 0,064 | ND | 0,5 | SDD | 0,906 | 0,819 | 0,375 | 0,761 | 0,469 | 0,881 | 0,636 | 1659 |
| TN659HC08 | 0,032 | ND | 4 | SDD | 0,5 | SDD | 0,125 | ND | 0,32 | SDD | 1055 | 1363 | 1381 | 0,725 | 1486 | 2482 | 0,878 | 0,907 |
| TN87HC09 | 0,125 | ND | 4 | SDD | 0,032 | S | 0,016 | ND | 0,016 | S | 0,697 | 1365 | 0,472 | 0,558 | 0,503 | 0,617 | 0,303 | 2681 |
| TN452HC15 | 0,032 | ND | 0,5 | S | 0,25 | SDD | 0,125 | ND | 0,125 | S | 1899 | 3504 | 1213 | 2489 | 0,411 | 1066 | 0,649 | 2711 |
| TN33HC06 | 1 | ND | 16 | R | 0,5 | SDD | 0,25 | ND | 0,25 | SDD | 0,518 | 0,880 | 0,971 | 0,874 | 1792 | 7426 | 1342 | 10,307 |
| TN460HC13 | 0,016 | ND | 0,5 | S | 0,016 | S | 16 | ND | 8 | R | 0,238 | 2184 | 1845 | 1313 | 0,568 | 1319 | 0,392 | 3028 |
| TN80HC15 | 0,5 | ND | 32 | R | 0,25 | SDD | 0,032 | ND | 0,008 | S | 2277 | 11,320 | 1563 | 2886 | 3320 | 0,490 | 2572 | 1425 |
| TN87HC15 | 0,5 | ND | 32 | R | 0,25 | SDD | 0,032 | ND | 0,008 | S | 2013 | 11,097 | 2016 | 2845 | 3472 | 0,444 | 2604 | 1262 |
I interpretation, ND Not determined due to lack of validated clinical breakpoints, S susceptible, SDD dose-dependent susceptible, R resistant, MIC in μg/ml